Small non-coding RNAs and genomic imprinting

Royo, Hélène; Bortolin, Marie‐Line; Seitz, Hervé; Cavaillé, Jérôme

doi:10.1159/000090820

Cited by 60 publications

(55 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, in addition to their function in ribosomal maturation, snoRNA species or their derivates have been implicated in processes associated with carcinogenesis, for example, alternative splicing events (Kishore and Stamm, 2006) and genomic imprinting (Royo et al, 2006). In PCa, snoRNA U50 has been reported to be a candidate tumor-suppressor gene and a mutation in its sequence has been associated with clinically significant disease (Dong et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer

et al. 2011

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most frequent male malignancy and the second most common cause of cancer-related death in Western countries. Current clinical and pathological methods are limited in the prediction of postoperative outcome. It is becoming increasingly evident that small non-coding RNA (ncRNA) species are associated with the development and progression of this malignancy. To assess the diversity and abundance of small ncRNAs in PCa, we analyzed the composition of the entire small transcriptome by Illumina/ Solexa deep sequencing. We further analyzed the micro-RNA (miRNA) expression signatures of 102 fresh-frozen patient samples during PCa progression by miRNA microarrays. Both platforms were cross-validated by quantitative reverse transcriptase-PCR. Besides the altered expression of several miRNAs, our deep sequencing analyses revealed strong differential expression of small nucleolar RNAs (snoRNAs) and transfer RNAs (tRNAs). From microarray analysis, we derived a miRNA diagnostic classifier that accurately distinguishes normal from cancer samples. Furthermore, we were able to construct a PCa prognostic predictor that independently forecasts postoperative outcome. Importantly, the majority of miRNAs included in the predictor also exhibit high sequence counts and concordant differential expression in Illumina PCa samples, supported by quantitative reverse transcriptase-PCR. Our findings provide miRNA expression signatures that may serve as an accurate tool for the diagnosis and prognosis of PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Most of the initial 82 miRNAs with predominant production in placental tissue showed no postdelivery clearance, suggesting that maternal tissues other than blood cells contributed to their presence in maternal plasma. It is noteworthy that 21 of 24 genes encoding pregnancy-associated miRNAs present in maternal plasma were clustered on 19q13.42 or 14q32, which are critical regions for placental growth and embryonic development (12)(13)(14)(15). The concentrations of circulating pregnancyassociated miRNAs in maternal plasma showed a time dependence as pregnancy progressed into the third trimester.…”

Section: Discussionmentioning

confidence: 99%

Identification of Pregnancy-Associated MicroRNAs in Maternal Plasma

Miura¹,

Miura²,

Yamasaki³

et al. 2010

Clinical Chemistry

183

178

View full text Add to dashboard Cite

show abstract

“…Importantly, three genomic loci at chromosomes 14, 19, and X harbor 25 miRNAs down-regulated in EOC (Fig. S5), and these loci may be regulated through imprinting or epigenetic mechanisms (40). Therefore, we analyzed IOSE and EOC cell lines by real-time RT-PCR for expression of 18 from these 25 clustered miRNAs and 5 miRNAs not located in these clusters.…”

Section: Microrna Expression Profiles Classify Malignant From Nonmalimentioning

confidence: 99%

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer

Zhang¹,

Volinia

Bonome

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

474

430

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are an abundant class of small noncodingRNAs that function as negative gene regulators. miRNA deregulation is involved in the initiation and progression of human cancer; however, the underlying mechanism and its contributions to genome-wide transcriptional changes in cancer are still largely unknown. We studied miRNA deregulation in human epithelial ovarian cancer by integrative genomic approach, including miRNA microarray (n ‫؍‬ 106), array-based comparative genomic hybridization (n ‫؍‬ 109), cDNA microarray (n ‫؍‬ 76), and tissue array (n ‫؍‬ 504). miRNA expression is markedly down-regulated in malignant transformation and tumor progression. Genomic copy number loss and epigenetic silencing, respectively, may account for the downregulation of Ϸ15% and at least Ϸ36% of miRNAs in advanced ovarian tumors and miRNA down-regulation contributes to a genome-wide transcriptional deregulation. Last, eight miRNAs located in the chromosome 14 miRNA cluster (Dlk1-Gtl2 domain) were identified as potential tumor suppressor genes. Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer.Dlk1-Gtl2 domain ͉ noncoding RNA

show abstract

Small non-coding RNAs and genomic imprinting

Cited by 60 publications

References 144 publications

Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer

Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer

Identification of Pregnancy-Associated MicroRNAs in Maternal Plasma

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer

Contact Info

Product

Resources

About